Caizhong News Agency, November 13th - Zaiding Pharmaceutical (09688/ZLAB) released its third quarter report as of September 30, 2024. In the third quarter of 2024, the company's net product revenue was $102 million, a year-on-year increase of 47%, mainly due to the sales growth of Weiweijia, Zele, and Nuozaile. Among them, Wei Weijia's income was 27.3 million US dollars, while the income of Ze Le and Niu Zaile were 48.2 million US dollars and 10 million US dollars respectively. R&D expenses amounted to $66 million, sales, general and administrative expenses amounted to $67.2 million, operating losses amounted to $67.9 million, net losses amounted to $41.7 million, and a loss of $0.04 per common share.
As of September 30, 2024, the company's cash reserves were $716 million, a decrease from $730 million as of June 30, 2024.
Recently, KarXT has achieved positive results in bridging research for schizophrenia in China, and is expected to submit a marketing authorization application in early 2025. In addition, ZL-1310 has shown promising potential in the global phase 1 study of small cell lung cancer, and it is expected that three products will be commercially launched in China by the end of 2024. The company is continuously advancing its innovative drug pipeline, demonstrating promising market prospects.